Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Corporate Authors:
      HIV Outpatient Study (HOPS) Investigators
    • المصدر:
      Publisher: Wiley Country of Publication: England NLM ID: 100897392 Publication Model: Print Cited Medium: Print ISSN: 1464-2662 (Print) Linking ISSN: 14642662 NLM ISO Abbreviation: HIV Med Subsets: MEDLINE
    • بيانات النشر:
      Publication: Oxford : Wiley
      Original Publication: Oxford : Blackwell Science, c1999-
    • الموضوع:
      Hypophosphatemia*/chemically induced ; Hypophosphatemia*/epidemiology; Adenine/*analogs & derivatives ; HIV Infections/*drug therapy ; Organophosphonates/*adverse effects ; Reverse Transcriptase Inhibitors/*adverse effects; Adenine/adverse effects ; Adult ; Antiretroviral Therapy, Highly Active ; Female ; Humans ; Incidence ; Male ; Prospective Studies ; Risk Factors ; Tenofovir ; Treatment Outcome ; United States/epidemiology
    • نبذة مختصرة :
      Objectives: Cases of hypophosphataemia (often coincident with renal dysfunction) have been reported in HIV-infected patients taking tenofovir disoproxil fumarate (TDF), but randomized placebo-controlled trials of HIV-infected persons with normal baseline renal function have found a comparable incidence of hypophosphataemia in the TDF and placebo groups. We assessed the incidence of grade 2 and higher hypophosphataemia in the HIV Outpatient Study (HOPS).
      Methods: We analysed a prospective cohort of patients who initiated either a TDF-containing highly active antiretroviral therapy (HAART) regimen [TDF-exposed (TDF+) group; n = 165] or a TDF-sparing HAART regimen [TDF-unexposed (TDF-) group; n = 90], and who had normal baseline phosphate and creatinine values.
      Results: The TDF+ and TDF- groups had comparable median follow-up times (10.9 vs 8.8 months, respectively; P = 0.18) and number of phosphate measurements (median = 3 for both) and were similar on most clinical and demographic factors. During follow up, 12.7% of TDF+vs 6.7% of TDF-patients developed grade 2 hypophosphataemia (2.0-2.4 mg/dL), and 2.4% of TDF+ patients vs 0% of TDF-patients developed grade 3 hypophosphataemia (1.0-1.9 mg/dL); none developed grade 4 hypophosphataemia (<1.0 mg/dL). The incidence of grade 2 or higher hypophosphataemia was 16.7 per 100 person-years among TDF+ patients vs 8.0 per 100 person-years among TDF-patients (P = 0.11).
      Conclusions: The incidence of hypophosphataemia was somewhat elevated in HOPS patients who took TDF-containing HAART compared with those who took TDF-sparing HAART during the first 1 to 2 years of observation, but the difference was not statistically significant. Longer follow-up of a larger population is needed to determine if this trend towards an association achieves statistical significance and to evaluate the clinical consequences of hypophosphataemia.
    • الرقم المعرف:
      0 (Organophosphonates)
      0 (Reverse Transcriptase Inhibitors)
      99YXE507IL (Tenofovir)
      JAC85A2161 (Adenine)
    • الموضوع:
      Date Created: 20060824 Date Completed: 20070702 Latest Revision: 20151119
    • الموضوع:
      20221213
    • الرقم المعرف:
      10.1111/j.1468-1293.2006.00407.x
    • الرقم المعرف:
      16925731